Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed small cell lung cancer,extensive stage disease.~* Measurable or evaluable disease~* No previous chemotherapy~* Able to perform activities of daily living with minimal assistance~* Adequate hematological, live and kidney function~* Provide written informed consent~Exclusion Criteria:~* Limited stage disease~* PEG or G tubes~* Hemoptysis~* Abdominal fistula, perforation, or abscess within the previous 6 months~* Women who are pregnant or lactating~* Proteinuria~* Serious nonhealing wound, ulcer, or bone fracture~* Evidence of bleeding diathesis or coagulopathy~* Uncontrolled or serious cardiovascular disease~* Uncontrolled brain metastasis~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days; Fine needle aspiration within 7 days~* Patients requiring full-dose anticoagulation must be on a stable dosing schedule prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).